Retatrutide Research: What the Early Work and Phase 3 Tell Us

What do the studies tell us so far?

Less hunger or a lower number on the scale may come first. Early retatrutide work also tracked blood sugar, pulse, and stomach trouble. Phase 1 followed 72 adults with type 2 diabetes. It gave the first clues about how long the drug stayed in blood and what went wrong.

Phase 2 studied people with obesity, type 2 diabetes, or fatty liver. The obesity group had the largest weight loss yet seen for this drug family. Phase 3 is now taking in more people.

The drug copies three hormone messages. One curbs hunger and slows food leaving the stomach. Another helps release insulin after a meal and affects stored fat. Glucagon, the third hormone, raises the fuel the body burns. No approved drug of this kind copies all three. At the top Phase 2 amount, people lost 24.2% of their weight on average.

These are trial findings, not an approved drug label. Retatrutide is still being tested. More Retatrutide research appears below.

When you read that weight figure, remember it is one group's average, not a forecast of what your body will do or how your health will change.

How does retatrutide act inside your body?

Scientists built retatrutide from many small pieces found in protein. A strip of fat helps the drug cling to albumin, a protein in the clear part of blood. That slows the drug's exit and made a weekly trial shot possible ^[4].

Powerful lab pictures found that retatrutide could join three body message sites ^[3]. Each link has a different job:

• Hunger and digestion: The lab team calls this message GLP-1. It curbed hunger, slowed food leaving the stomach, and helped release insulin when sugar rose.
• Insulin and fat: Another link helped release insulin and changed how fat was handled. Scientists built this as the main link.
• Fuel use: The third link copied glucagon. It helped the liver break down fat and raised fuel use at rest.

The GLP-1 link and the other two may curb hunger, raise fuel use, and keep blood sugar from climbing too far ^[3]. Those lab tests explain what may happen inside the body. They don't prove a result or long-term safety for you.

What did Phase 1b find in its first human test?

The Phase 1b trial followed 72 adults with type 2 diabetes for 12 weeks ^[4]. Staff raised the test amounts in steps. The main findings were clear:

• The drug stayed for about 6 days. That span supported one shot each week. The retatrutide half life page explains what that means.
• People at the top amount lost more weight than those given placebo. A placebo is a shot with no drug. A 90% math check backed the group difference, but it can't predict one person's loss over 12 weeks.
• At 3 mg, blood sugar before food fell.
• Health problems affected 63%. Most were stomach problems. The researchers found the safety signs acceptable at every test amount.
• The shot went under the skin once a week. No other way was tested in people.

Staff started low and raised the amount slowly. Phase 2 kept that method because it may help the stomach adjust ^[7].

What changed for people in the three Phase 2 groups?

Obesity trial ^[1]: The trial followed 338 adults. On the usual height-and-weight chart, they scored at least 30, or 27 with another health problem. The report writes the four amounts as 1/4/8/12 mg. Chance set the drug and placebo groups. The 12 mg line gives average weight change at 48 weeks.

Stomach problems rose with the test amount. Most were mild to moderate. Resting pulse rose most near 24 weeks. At 12 mg, 18% left the trial.

Type 2 diabetes trial ^[2]: The trial followed 281 adults. Their usual-sugar blood test began between 7.0–10.5%. Groups got weekly shots, placebo, or another drug. At 12 mg, that blood test fell 2.02 points by week 24, against 0.01% with placebo. Weight fell 16.94%, against 3.00%, by week 36. No one died or had severe low blood sugar.

Fatty liver trial ^[5]: The work followed 98 people with obesity and fatty liver for 48 weeks. They started with at least 10% liver fat. A scan measured what share of the liver was fat. The report lists the four separate amounts as 1/4/8/12 mg. At 24 weeks, every drug group lost liver fat while placebo rose 0.3%. At 12 mg, it fell 82.4%. Then 86% reached normal liver fat below 5%. The improvement still held at 12 mg.

What are Phase 3 trials still trying to learn?

Phase 3 is still under way in mid-2026. The weight trials numbered 1, 2, and 3 study obesity and diabetes. Trial 1 studies obesity alone. Trial 2 is part of Phase 3. Other trials check the heart and kidneys. One compares retatrutide with tirzepatide. No Phase 3 result has been made public.

Reviews help put the Phase 1/2 work in place. Long-term safety is still a Phase 3 question. A 2025 review called the roughly 24% weight loss a large step past older drugs ^[6]. Another 2025 review said slow increases helped people bear stomach trouble ^[7]. A third 2025 review said the weight loss might come near that seen after bariatric surgery ^[8]. That's an idea to test, not a result.

A 2026 review explained why drugs can copy several food-linked hormones at once ^[13]. A 2025 review looked at kidney and heart health in people with diabetes and obesity ^[11]. Retatrutide trials are now checking those same kinds of people.